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ANTIRETROVIRAL THERAPY DOSE ADJUSTMENTS BASED ON
CALCULATED CREATININE CLEARANCE
J. SHAVADIA, G. TESFALDET and M. TWAHIR
ABSTRACT
Background: Whereas therapy for HIV is dependent on level of creatinine clearance, most
laboratories locally only report an absolute creatinine value. There is likelihood that the
patients already on antiretroviral therapy (ART) may have required dosage adjustment at
the time of initiation of therapy or sometime during ongoing therapy. This paper explores a
group of patients who are already on ART to determine their creatinine clearance and assess
the need for ART dose adjustment.
Objective: To determine the proportion of stable HIV outpatients who have a documented
creatinine clearance (CrCI) and the proportion requiring antiretroviral drug dose adjustments
depending on their creatinine clearance.
Design: Retrospective observational study.
Setting: One stop HIV medical clinic, Aga Khan University Hospital, Nairobi between
January and February 2007.
Subjects: Ninety three patients seen.
Results: None of the study subjects had a calculated creatinine clearance in their medical
records. Fifteen of the 93 patients (16.1%) had no serum creatinine performed in the twelve
months preceding the last clinic visit. Nine of the remaining 78 patients (11.5%) had evidence
of renal insufﬁciency (CrCI <60mls/min) as estimated by the Cockroft Gault method, with
six patients (7.7%) requiring dose adjustments to the one or more drugs in their antiretroviral
therapy (ART) regime (CrCI <50mls/min).
Conclusion: It is imperative to have a CrCI prior to and during follow up of patients with
HIV disease on ART to reduce potential drug toxicities and interactions, especially with the
increased utilisation of newer and potentially more nephrotoxic antiretrovirals.

INTRODUCTION
Although the Infectious Disease Society of
America (IDSA) recommends measurement of
renal function prior to initiation of antiretroviral
therapy (ART) (1) and regular screening of renal
chemistry while on ART, majority of the patients
in resource constrained settings do not conform
to these guidelines largely due to ﬁnancial
constraints. Those that attempt to measure
renal chemistries, use serum creatinine as an
estimation of the renal function. However, serum
creatinine alone is not ideal for the measurement
of renal function. Many HIV positive patients
present late in our set-up. At presentation, these
patients usually have weight loss with signiﬁcant
reduction in muscle mass. Serum creatinine
is inﬂuenced by muscle mass even without a

change in glomerular ﬁltration rate. The current
recommendation is that the glomerular ﬁltration
rate (GFR), rather than serum creatinine, be used
to assess the degree of renal impairment and to
follow the course of renal disease.
Several modalities have been utilised in
the general population to determine the GFR. A
twenty four hour urine collection and subsequent
measurement of creatinine clearance (CrCl)
was once commonly used. However, attendant
problems of accurate urine collection, timing,
convenience and cost have relegated this method
predominantly to in-patients where this can
be supervised. It is now acceptable to estimate
creatinine clearance using either Cockcroft
Gault or the modiﬁcation of diet in renal disease
(MDRD) formula (2,3). Based on this, most
guidelines on ART recommend antiretroviral
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dose adjustment based on calculated GFR rather
than serum creatinine levels (1-4).
Although highly active antiretroviral
therapy (HAART) has revolutionised the
treatment of HlV-infected patients, new problems
have emerged, such as viral resistance, drug
interactions and drug-related adverse effects.
This has therefore made ARV drug prescription
increasingly
complex,
predisposing
to
prescription errors, both in hospitalised patients
and the out-patient setting (5-9). In a review of
209 admissions over a one-year period, Rastegar
et al (7) reported that in 16.7% of hospitalised
HIV-infected patients, ARV medication errors
were due to incorrect amount or frequency of
dosage; over half of these errors were attributable
to failure to appropriately adjust dosage for renal
insufﬁciency.
Several antiretroviral medications may
have renal adverse events. Conversely, many
patients with already impaired renal function
have increased incidence of side effects of ART
such as neuropathy, lipodystrophy and Fanconi
syndrome (1). There have been several case
reports of renal failure in patients on teno fovir
(10-14), most of whom had normal renal function
prior to initiation of ART. This deterioration of
renal function is potentially worse in patients who
have an impaired baseline creatinine clearance.
Wools-Kaloustian et al (15) performed a
cross-sectional study in an ARV-naive Kenyan
population and found baseline renal insufﬁciency
deﬁned as a CrCI <60mls/min in 11.5% and CrCl
<50mls/min in 4.8% of the study population.
With an HIV prevalence rate of 7.8% (16) in
the Kenyan population of 37 million, over two
million would be HlV-infected of whom, close to
300,000 HIV infected patients may have potential
baseline renal insufﬁciency. When these patients
are commenced on HAART, close monitoring of
their renal function would be required, both prior
to and during therapy.
Whereas therapy of HIV is dependent
on level of creatinine clearance, most of the
laboratories in our country only report creatinine
as an absolute value. There is a likelihood that
the patients already on ART may have required
dosage adjustment at the time of initiation of
therapy or sometime during ongoing therapy.
This paper explores this group of patients
who are already on ART and determine their
creatinine clearance thereby determining those
whose treatment should have been adjusted.
MATERIALS AND METHODS
One hundred and twenty seven patient records
which met criteria for inclusion and excluded
thirty four who either were not on ART or had
insufﬁcient data on their age, gender and weight.
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Analysis was therefore performed for ninety-three
patients’ records between January and February
2007. Since these patients re-attended the outpatient clinic after February 2007, the last date
of appointment in the year 2007 was noted and
the following parameters obtained: Age, gender
and race; weight at the last appointment date;
outpatient serum creatinine in the preceding 12
months of the last review date. We only utilised
serum creatinine done as an out-patient since this
parameter may change when patients are acutely
unwell; ART regime and dosing as per the last
review date; last available CD (4) count and
plasma viral load within the preceding l2mo.
Every eligible patient had a serum
creatinine clearance calculated using both the
Cockcroft-Gault and simpliﬁed MDRD method.
Dosing recommendations was utilised as per the
guidelines for the use of antiretroviral agents in
HIV -infected adults and adolescents (15).
RESULTS
The mean age was 42.8 years (25 - 67 years) and
males comprised 61.3% of the study population
giving a male: female ratio of 1.6: 1. All our
patients were black Africans.
Figure 1
ART use was distributed as follows
80
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TDF = Tenofovir
AZT = Zidovudine
d4T = Stavudine
ABC = Abacavir
ddI = Didanosine

FTC = Emtricitabine
3TC = Lamivudine
EFV = Efavirenz
NVP = Nevirapine
LPV /r = Lopinavir/
Ritonavir

Seventy eight point two per cent of patients had
CD4 counts > 200 with the mean CD4 count of 385
cells/mm3 (2-l304 cells/mm3). On analysis of the
plasma viral load data available for 85 (91.4%)
patients, 63 (74.1%) patients had undetectable
viral loads (<50 copies/ml).
None of the study patients either had
a calculated creatinine clearance recorded in
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their medical records or had had ART dosages
adjusted. Fifteen of the 93 patients evaluated
(16.1%) had not had a serum creatinine done
in the 12 months preceding the last clinic visit.
Of the 78 patients who had data on their serum
creatinine, nine (11.5%) had a CrCl <60mls/min
and six (7.7%) had a CrCI <50mIs/min as per the
Cockroft Gault method while 7.6% and 3.8% had
CrCI <60mls/min and <50mls/min respectively,
as per the simpliﬁed MDRD formula.
DISCUSSION
None of the study patients had a documented
calculated creatinine clearance on which their
ART dosing was based on. This is not in keeping
with the recommendations either from the
guidelines for the use of antiretroviral agents
in HIV-infected adults and adolescents (l7)
or the IDSA guidelines (1) which recommend
ART dosing based on the CrCI. It is also not in
tandem with the WHO guidelines (l8) for ARV
monitoring in regional referral centres where
full serum chemistries have been advocated as
opposed to resource-limited settings at primary
health care and district levels.
From our study cohort, we also found
7.7% of the patients had a CrCI <50mls/min,
reﬂecting the proportion of patients who require
dose adjustment in their ART, mainly in the
nucleoside and nucleotide reverse transcriptase
inhibitor dosing. Although not our primary
aim, it would have been interesting to identify
the proportion and nature of adverse events in
this cohort of patients who actually had renal
insufﬁciency and required ART dose adjustment.
The predominant agents requiring dose
modiﬁcation from our study included: tenofovir,
emtricitabine, stavudine and lamivudine. An
additional 3.8% of the study patients had a
CrCI between 51-60mls/min and will therefore
require close monitoring of their renal function.
The need for dose adjustment of ART in patients
with chronic kidney disease is under-appreciated
by physicians offering care to patients with HIV
disease.
Over 60% of the patients in our study
were on a tenofovir based ARV regime. However,
the guidelines for antiretroviral therapy in Kenya
(19) recommend the use of either stavudine or
zidovudine as the nucleoside backbone. The
difference is likely to be due to the simplicity of
use and safety proﬁle of tenofovir, hence physician
and patient preferences in using this drug.
With increasing use of potentially
nephrotoxic antiretrovirals, this calls for
physicians taking care of patients with HIV
disease to be vigilant in monitoring renal function
and calculate the CrCI both prior and during
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treatment. It also adds to the growing momentum
that CrCI rather than absolute creatinine values
be reported by all laboratories to facilitate
drug dosing and reduce toxicity proﬁles due to
inadvertent drug overdosing.
The IDSA guideline recommends use of
the Cockroft-Gault formula for calculation of the
CrCI to base drug dosing on. In our study, the
Cockroft-Gault formula was able to identify twice
as many patients with an estimated CrCI <50mls/
min, compared to the modiﬁed MDRD method.
Due to this superiority and the ease of calculation
of the CrCI using the Cockroft-Gault equation,
this should probably be the recommended
method in our population. However, this formula
has neither been validated in our population nor
in patients with HIV disease. Therefore, more
local and regional data comparing the calculated
methods of creatinine clearance to urinary
clearance of exogenous ﬁltration markers is
required in patients with HIV disease.
Although not a primary goal of our
study, we also noted that none of our patients had
routine urinalysis done to test for proteinuria.
Proteinuria is one of the presentations of HIV
related kidney disease. This would have provided
further supporting evidence to identify patients
with kidney injury.
In keeping with our study, available local
and regional evidence suggest that approximately
11.5% of ARV-naive HIV infected patients have
baseline renal insufﬁciency (CrCI <60mls/min)
(15). However, our study demonstrated a higher
proportion of patients 7.7% versus 4.8% (5) with
hitherto undetected signiﬁcant renal dysfunction
of CrCI <50ml/min requiring dosage adjustment
of the ARV prescription. This implies these
patients are exposed to higher drug toxicity and
nephrotoxic effects of the medication.
In conclusion, the results of this study provides
regional evidence, in addition to other locoregional studies (12), on the estimates of HIV
infected patients requiring adjustments to their
ARV regime based on their CrCI. It also cautions
all treating physicians to calculate an estimated
GFR both prior to, and after initiation of ART
to ensure appropriate antiretroviral dosage
and hence prevent attendant ARV toxicity.
In addition, it calls for laboratories to report
CrCI using the Cockroft Gault method rather
than absolute creatinine values to facilitate
improvement in care for patients with HIV
disease.
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